In approximately 85% of Ewing sarcomas, chromosomal translocations give rise to the chimeric gene EWS/FLI, encoding the N-terminus of the RNA binding protein EWS fused to the DNA-binding domain of the ETS protein FLI-1. EWS/FLI is a stronger transcriptional activator than wild-type FLI-1, although both proteins bind to the same DNA sequences in vitro. In addition, EWS/FLI, but not FLI-1, is a transforming oncogene in NIH3T3 ®broblasts. EWS/FLI is thought to transform through its ability to deregulate the expression of target genes. We introduced several point mutations into the ETS domain of EWS/FLI that abolished DNA-binding activity. Although two of these mutations disrupted the transforming activity of EWS/FLI, one mutated protein containing a substitution of isoleucine 347 with glutamic acid (I347E) retained diminished transforming activity. In addition, EWS/FLI I347E did not activate expression of the endogenous EWS/FLI target gene manic fringe (MFNG). These studies demonstrate that a portion of the oncogenic activity of EWS/FLI is independent of FLI DNA-binding activity.
The majority of somatically acquired chromosomal translocations in human tumors involve transcription factors (Barr, 1998; Look, 1997; Rabbitts, 1994) . The resulting chimeric transcription factors are thought to contribute to tumorigenesis through aberrant transcriptional control of critical genes that govern cell survival, proliferation, and/or dierentiation. Ewing sarcoma, a pediatric solid tumor, is uniquely characterized by a speci®c t(11;22)(q24;q12) chromosomal translocation found in over 85% of the cases (Turc-Carel et al., 1988) . This genetic alteration generates a novel inframe fusion gene between sequences encoding the Nterminus of the RNA binding protein EWS, and the Cterminus of FLI-1, a member of the ETS family of transcription factors (Delattre et al., 1992) . Other less frequent chromosomal translocations involve the same region of EWS and one of several ETS genes; ERG, ETV-1, E1AF, or FEV (Jeon et al., 1995; Peter et al., 1997; Sorensen et al., 1994; Urano et al., 1996) . Taken together, these chromosomal translocations provide compelling genetic evidence that expression of one of several EWS/ETS chimeric proteins is a required event in the genesis of Ewing sarcoma. Related fusion proteins in which the RNA binding domains of EWS, or the related protein TLS/FUS, are replaced by DNA binding domains from dierent transcription factors have been identi®ed in four dierent types of human sarcoma in addition to Ewing sarcoma (Crozat et al., 1993; Labelle et al., 1995; Ladanyi and Gerald, 1994; Panagopoulos et al., 1996; Rabbitts et al., 1993; Zucman et al., 1993) and also in acute myeloid leukemia (Ichikawa et al., 1994) .
Several lines of experimental evidence led to a working hypothesis in which EWS/FLI transforms cells through altered transcriptional regulation of key genes that are speci®cally targeted by the FLI DNA binding domain in the fusion protein. First, EWS/FLI binds DNA in vitro with the same speci®city as wildtype FLI-1 (Mao et al., 1994) , but EWS/FLI is a stronger transcriptional activator (Bailly et al., 1994; May et al., 1993b; Ohno et al., 1993) . The activity of the fusion protein can also be distinguished from normal FLI-1 by its transforming ability. EWS/FLI, but not FLI-1, transforms NIH3T3 cells, and this activity requires both the EWS portion of the fusion protein, which contributes transcription activation activity, and the ETS domain, which mediates sequence-speci®c DNA binding (May et al., 1993a) .
To investigate the hypothesis that DNA binding activity is required for EWS/FLI-mediated transformation, we introduced several dierent amino acid substitutions that disrupted DNA binding activity of EWS/FLI. Two mutations have been characterized previously that disrupt DNA binding activity of EWS/ FLI; substitution of tryptophan 321 to arginine (W321R), and replacement of arginines at codon 337 and 340 with leucines (R337, 340L) (Bailly et al., 1994) . We also engineered a substitution of isoleucine 347 with glutamic acid in EWS/FLI (EWS/FLI I347E). The same amino acid substitution in ETS-1 and ETS-2 abolished their DNA-binding and transactivation activities (Soudant et al., 1994) . The DNA binding properties of wild-type and mutant EWS/FLI were analysed by electrophoretic mobility shift assay (EMSA) (Figure 1 ). Wild-type EWS/FLI bound strongly to a consensus FLI binding site (lane 2). However, all of the point mutations (lanes 3 ± 5), as well as the previously described mutant EWS/FLI containing a 54 amino acid deletion within the ETS domain (de154) (lane 6) (May et al., 1993a) failed to bind DNA. Our conditions were adequate to detect the weak binding of the ETS protein PU.1 which has a dierent sequence speci®city (lane 7). The failure to bind to DNA was not due to a lack of protein, as similar quantities of all proteins were used for the EMSA (data not shown).
We compared the transforming activity of EWS/ FLI, EWS/FLI containing the point mutations described above, EWS/FLI del54, and a vector control. NIH3T3 cells were transduced with retroviruses that expressed epitope-tagged versions of each protein and transformation was assayed by anchorageindependent growth in soft agar. All mutant proteins were expressed at roughly equivalent levels in transduced cells (data not shown). Representative ®elds of colonies growing in soft agar are shown in Figure 2a . The average number of colonies greater than 50 mm in size obtained with each construct is displayed in Figure 2b . As expected, the expression vector did not confer anchorage independent growth, indicating that our assay conditions were not susceptible to spontaneous transformation. Neither the point mutants EWS/FLI W321R and EWS/FLI R337, 340L, nor EWS/FLI del54 formed macroscopically visible colonies. Surprisingly, loss of DNA binding activity did not completely disrupt the oncogenic activity of EWS/FLI I347E. Although the number of large colonies formed in soft agar was decreased compared to wild-type EWS/FLI, EWS/FLI I347E consistently produced macroscopically visible colonies in soft agar as large as those observed with EWS/FLI in seven independent experiments. The average number of colonies formed by EWS/FLI I347E was 24% relative to colony formation by EWS/FLI. Immunocytochemical analysis con®rmed that the mutations did not alter the subcellular localization of EWS/FLI (data not shown).
To con®rm that the transformed cells indeed expressed the introduced fusion proteins, we cultured individual and pooled transformed colonies, and assayed levels of wild-type and EWS/FLI I347E expression by Western blot (Figure 3a ). Both EWS/ FLI (lanes 1 ± 6) and EWS/FLI I347E (lanes 7 ± 12) were expressed in colonies that grew in soft agar, with EWS/FLI I347E consistently expressed at higher levels. This dierence in expression level was also observed in the transduced cells before plating in soft agar, and therefore was not the result of selective pressure during growth in agar. To verify that there was no residual DNA binding activity associated with the high levels of EWS/FLI I347E, we examined DNA binding activity in protein extracts from the parental NIH3T3 cells, and in cells transformed by EWS/FLI or EWS/FLI I347E ( Figure 3b ). NIH3T3 cells contain a high level of endogenous ETS-like DNA binding activity (lane 1). The activity contributed by EWS/FLI is apparent as a more rapidly migrating band on the gel (lanes 2 and 8), which can be easily distinguished from the cellular background by addition of an antibody against the FLAG epitope, which is contained in both EWS/FLI proteins. Binding of the antibody caused a further retardation of EWS/FLI speci®c complexes (lane 5). This speci®c eect was not observed following addition of an equal amount of a control antibody (lane 8). No residual DNA binding activity of EWS/FLI I347E was observed (lanes 3, 6, and 9), even upon overexposure of the gel. These results con®rmed that EWS/FLI I347E retained transforming ability despite ablation of DNA binding activity.
An additional possibility was that while the I347E mutation disrupted binding to the consensus FLI binding site, it may still have allowed binding to related sites with a slightly varied sequence. Binding to alternative sites may be possible, as wild-type PU.1 contains a glutamic acid in the position corresponding to the I347E mutation in EWS/FLI (Pio et al., 1996) . Therefore, we evaluated the ability of wild-type and mutant EWS/FLI to bind to the consensus sites for the ETS proteins PU.1 and ETS1 by EMSA. No DNA binding activity of any of the mutated proteins was The arrow points to the EWS/FLI speci®c band shift. The arrow head indicates the PU.1 speci®c shift. All cDNAs were cloned into pBSKS(+) vector (Stratagene) to allow in vitro transcription with T7 polymerase. The sequence of the constructs generated using the polymerase chain reaction (PCR) was con®rmed by sequence analysis. The full length coding sequences for human FLI-1 and EWS/FLI with a Type I breakpoint (Delattre et al., 1992) were ampli®ed by PCR. The point mutations were introduced into the EWS/FLI type I cDNA by PCR-based strategy. The EWS/FLI del54 mutant was generated as described previously (May et al., 1993a) . The clone containing the full length human PU.1 cDNA (GenBank accession number X52056) transcribed under the control of T7 polymerase was a generous gift from Dr Clare Sample, St Jude Children's Research Hospital. Electrophoretic mobility shift assays were carried out with 3 ml of in vitro translated proteins synthesized using the TNT coupled reticulocyte lysate systems (Promega) and 320 fmol of an oligonucleotide probe containing a consensus FLI binding site (GGGA-TAAACGGAAGTGGT) in conditions as described (Bosselut et al., 1990) . The protein-DNA complexes were resolved on a 5% native polyacrylamide gel in 0.56TBE observed with the PU.1 consensus or the ETS1 consensus binding sites (data not shown).
A mutated protein that lacks DNA binding activity would not be expected to activate transcription of target genes. As a physiologically relevant test of transcriptional activity of EWS/FLI I347E, we evaluated endogenous expression of the EWS/FLI target gene MFNG (May et al., 1997) in our experimental system (Figure 4a ). As reported previously, expression of MFNG was strongly induced in NIH3T3 cells expressing EWS/FLI (lane 3), but not in parental cells, or cells expressing wild-type FLI-1 (lanes 1 and 2). Importantly, MFNG expression was not induced in cells expressing EWS/FLI I347E (lane 4). As expected, loss of DNA binding activity is directly associated with the loss of target gene activation.
Transformation of NIH3T3 cells is the best available assay to study the oncogenic activity of EWS/FLI in vitro. However, there may be dierences between the in vitro transformation assay and the tumorigenic process required for Ewing sarcoma formation in humans. Our data indicate that activation of the endogenous target gene MFNG is not required for transformation by EWS/FLI in vitro. We also examined several human Ewing sarcoma cell lines to determine if expression of MFNG is required for Ewing sarcoma cell growth. Only one of three cell lines expressed MFNG ( Figure  4b ). Thus, EWS/FLI can act as an aberrant transcription factor to activate expression of target genes, however this activity may not be the only mechanism involved in tumorigenesis.
The transforming activity of EWS/FLI I347E demonstrates that the oncogenic properties of EWS/ FLI are not strictly dependent on the DNA binding activity. A precedent for such complexity in transformation by chimeric transcription factors was demonstrated in studies of three tumor-associated fusion proteins: E2A/PBX1 derived from pre-B cell lymphoblastic leukemia, PAX3/FKHR found in alveolar rhabdomyosarcoma, and E2A/HLF found in pro-Bcell acute lymphoblastic leukemia. Mutational analyses of these fusion proteins showed that while transforma- (Lam et al., 1999; Muller et al., 1991) . Transformation assays were carried out as described by May et al. (1993a) with the following minor modi®cations. Following transduction and G418 selection, polyclonal populations of NIH3T3 cells were plated in 0.3% agar/1X IMDM in duplicate at a serum concentration of 15% in 35 mm dishes at a density of 1.8610 4 and 1.8610 3 cells per dish. Colonies were scored 3 weeks post-plating. Assays were repeated seven times for vector, EWS/FLI, and EWS/FLI I347E, and repeated four times for EWS/FLI W321R, EWS/FLI R337, 340L and EWS/FLI del54 tion did not require DNA-binding, the ability to interact with other proteins was required (Chang et al., 1997; Inukai et al., 1998; Lam et al., 1999) .
The lack of transforming activity of EWS/FLI W321R and R337, 340L indicates that these mutations may disrupt more than DNA binding activity. Indeed, W321, R337, and R340 are absolutely conserved in all ETS family members (Wasylyk et al., 1993) . Therefore mutation of these residues could disrupt the overall structure of the ETS domain in addition to ablating DNA binding activity. While I347 is also highly conserved among ETS family members, the substitution of isoleucine with glutamic acid at the same position is found within the ETS domain of PU.1. Therefore, this change can be accommodated in the ETS domain structure.
In light of our results, it would seem that the ETS domain in EWS/FLI serves critical functions in addition to DNA binding. Unlike homeodomaincontaining proteins, ETS family members bind DNA Cell extracts were prepared as described (Thayer and Weintraub, 1993) . 20 mg of total protein was resolved by SDS ± PAGE, and transferred to nitrocellulose. Epitope-tagged proteins were detected with the anti-FLAG M2 monoclonal antibody (Babco) at a concentration of 10 mg/ml and visualized with the peroxidaseconjugated anti-mouse antibody supplied with the ECL kit (Amersham) according to the manufacturer's recommendation. (b) Cell extracts from EWS/FLI I347E transformed cells do not contain residual EWS/FLI binding activity. An electrophoretic mobility shift assay was performed using cell extracts from NIH3T3 ®broblasts transduced with empty vector (7), or cells transformed by EWS/FLI (wt) or EWS/FLI I347E (m), and the FLI consensus binding site. Binding is shown in the absence of antibody (lanes 1 ± 3), in the presence of anti-FLAG antibody (lanes 4 ± 6), or in the presence of a non-speci®c isotype-matched control IgG1 (Sigma) (lanes 7 ± 9). The arrows indicate the binding due to the endogenous ETS-like binding activity, the EWS/FLI speci®c complex, and the EWS/FLI supershifted complex caused by the addition of anti-FLAG M2 antibody to the protein extract. For lanes 4 ± 9, 4 mg of the respective antibody was preincubated with 16 mg of whole cell extract at 308C for 20 min, prior to the addition of the probe. The remainder of the assay was performed as described in the legend to Figure 1 3) . The blot was probed in succession with MFNG and actin. Ewing sarcoma cell lines RD-ES and SK-ES-1 were obtained from ATCC, TC252 was a generous gift from Dr Timothy Triche, USC. RNA was extracted following lysis of the cells in Trizol reagent (Life Technologies), according to the manufacturer's speci®cations. 15 mg of total RNA was resolved on a 1.1% agarose/formaldehyde/MOPS gel. Following transfer to Hybond nylon membrane (Amersham), the RNA was immobilized with UV irradiation. Probes were radiolabeled using the PrimeIt random priming kit (Stratagene). The MFNG probe included nucleotide 1 to 1043 of the MFNG cDNA (GenBank accession number U94352), and was obtained as an EST clone #1482306 (Research Genetics). The FLI-1 probe was generated from nucleotide 1 to 1400 from the human FLI-1 cDNA, and the actin probe encompassed nucleotide 402 to 1256 of mouse b-actin (GenBank accession number X03672). Hybridizations were carried out as previously described (Kinzler et al., 1988) as monomers (Wasylyk et al., 1993) . While the ETS domain has been extensively characterized as a modular domain that mediates binding to the core DNA consensus motif GGAA/T (Nye et al., 1992; Seth et al., 1992) , a number of recent studies with ETS family proteins have shown that this domain may also mediate distinct functions such as interactions with heterologous proteins (Treisman, 1994) , associations with other ETS proteins (Carrere et al., 1998) , and even RNA binding activity (Hallier et al., 1996) . Thus, it is possible that the ETS domain may mediate critical protein-protein interactions, independently of DNA binding activity, that are required for transformation by EWS/FLI. A rigorous test of this interesting hypothesis awaits identi®cation of speci®c ETSmediated interaction partners for EWS/FLI.
Classically, transcription factors and RNA binding proteins are critical in the control of gene expression through transcription and post-transcription regulation, respectively. Increasing evidence shows that some proteins, exempli®ed by hnRNPK (Michelotti et al., 1996) and the Drosophila transcription factor bicoid (Dubnau and Struhl, 1996; Rivera-Pomar et al., 1996) , have the ability to act on both levels (Ladomery, 1997) . Of particular relevance with respect to EWS/FLI is the ETS family protein PU.1. Both FLI-1 and PU.1 are frequent targets of viral integration in Friend-virusinduced erythroleukemia (Ben-David and Bernstein, 1991) . PU.1 functions as a classical transcription factor to activate expression of a number of macrophage and myeloid-speci®c genes. However, PU.1 is also able to bind to RNA through its ETS domain, and can interact with several splicing proteins. Intriguingly, PU.1 can also interact with the EWS-related protein TLS/FUS via the ETS domain of PU.1 and alter TLS/ FUS in¯uenced splice site selection of a reporter construct (Hallier et al., 1998) .
The data presented in this manuscript clearly demonstrate that a component of EWS/FLI transforming activity is independent of DNA binding activity. This ®nding does not rule out a transcription-mediated mechanism of transformation through interactions with other transcription factors. However, it is also possible that the fusion protein plays a role through interactions with dierent classes of proteins that perform dierent functions. Perhaps the recurrent generation of chimeric genes combining components of EWS or TLS/FUS with transcription factor DNA-binding domains provides a powerful mechanism to simultaneously disrupt normal transcription and post-transcription regulation in solid tumors.
